Molecular Therapy — Nucleic Acids · 2022 · 10 citations · 31 references
PharmacyBiotechnologyInfectious DiseasesDrug DeliveryNanoparticle Drug DeliveryVirologyAntiviral TherapyGene Delivery VectorsNanocarriers For TherapeuticsNanomedicineNanoparticle Delivery SystemsAntiviral TherapeuticsExosome-based TherapyExosomesNanoparticle DeliveryNanoparticle Delivery VectorsSars-cov-2 InfectionViral Spike ProteinsVirally Derived Delivery Vectors
Emerging viral diseases, such as Ebola, SARS, MERS, and the pathogen causing COVID-19, SARS-CoV-2, present a challenge for the development of therapeutics because of strict biosafety handling procedures and rapid mutation of their genomes. To facilitate the development of an adaptable and testable therapeutic model system, a colostrum exosome-based nanoparticle delivery system, EPM (exosome-PEI matrix), that overcomes stringent biosafety containment, was used to mimic the expression of viral proteins. This system would greatly expand the number of laboratories actively participating in the screening of potential therapeutics. EPM technology can deliver both plasmid DNA and siRNA to both simulate viral gene expression and screen potential antiviral siRNA therapeutics. Using this nanoplatform, three key SARS-CoV-2 proteins (the spike glycoprotein, nucleocapsid, and replicase) were expressed in vitro and in vivo. In vitro, several viral gene-targeting siRNAs were screened to determine knockdown efficiency, with some siRNA duplexes resulting in 80%–95% knockdown of corresponding protein expression. Moreover, in vivo experiments introducing the spike protein and nucleocapsid by EPM resulted in the production of antibodies against the viral antigen, measured up to 45 d after target delivery. Together, these findings support the efficacy of the EPM delivery system to establish a model for screening antiviral therapeutics-reduced biosafety level. Emerging viral diseases, such as Ebola, SARS, MERS, and the pathogen causing COVID-19, SARS-CoV-2, present a challenge for the development of therapeutics because of strict biosafety handling procedures and rapid mutation of their genomes. To facilitate the development of an adaptable and testable therapeutic model system, a colostrum exosome-based nanoparticle delivery system, EPM (exosome-PEI matrix), that overcomes stringent biosafety containment, was used to mimic the expression of viral proteins. This system would greatly expand the number of laboratories actively participating in the screening of potential therapeutics. EPM technology can deliver both plasmid DNA and siRNA to both simulate viral gene expression and screen potential antiviral siRNA therapeutics. Using this nanoplatform, three key SARS-CoV-2 proteins (the spike glycoprotein, nucleocapsid, and replicase) were expressed in vitro and in vivo. In vitro, several viral gene-targeting siRNAs were screened to determine knockdown efficiency, with some siRNA duplexes resulting in 80%–95% knockdown of corresponding protein expression. Moreover, in vivo experiments introducing the spike protein and nucleocapsid by EPM resulted in the production of antibodies against the viral antigen, measured up to 45 d after target delivery. Together, these findings support the efficacy of the EPM delivery system to establish a model for screening antiviral therapeutics-reduced biosafety level.
31
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou, Xing‐Lou Yang, Xian-Guang Wang et al. · Nature · 2020 · 23.3K citations · Full text
Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes
Lydia Alvarez‐Erviti, Yiqi Seow, HaiFang Yin et al. · Nature Biotechnology · 2011 · 4.8K citations
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar, Valerie S. LeBleu, Hikaru Sugimoto et al. · Nature · 2017 · 2.6K citations
Medicine, Cancer Biology, Oncology +13
The Architecture of SARS-CoV-2 Transcriptome
Dong-Wan Kim, Joo-Yeon Lee, Jeong‐Sun Yang et al. · Cell · 2020 · 2.4K citations · Full text